To evaluate the association between serum uric acid (SUA) levels and prognosis in patients with nasopharyngeal carcinoma (NPC) treated with a comprehensive regimen of induction chemotherapy, intensity-modulated radiation therapy (IMRT), and adjuvant chemotherapy. A total of 182 patients with NPC treated at the Second Affiliated Hospital of Nanchang University between 2017 and 2021 were retrospectively analyzed. SUA levels were recorded at four time points: Pre-treatment, post-induction chemotherapy, post-IMRT and post-adjuvant chemotherapy. Based on the median post-adjuvant chemotherapy SUA level (350.48 µmol/l), patients were stratified into high (SUA >350 µmol/l) and low (SUA ≤350 µmol/l) groups. Survival outcomes were compared using Kaplan-Meier analysis and log-rank tests. Cox proportional hazards models were employed to identify independent prognostic factors. Changes in SUA levels over time were assessed using repeated-measures ANOVA. The high SUA group demonstrated improved 3-year overall survival (OS; P=0.037), progression-free survival (PFS; P<0.001), and distant metastasis-free survival (DMFS; P=0.001) compared with the low SUA group. No significant difference in locoregional relapse-free survival (P=0.41) was observed. Post-adjuvant chemotherapy SUA levels were an independent prognostic factor for OS, PFS and DMFS. Repeated-measures ANOVA showed a significant reduction in SUA levels post-IMRT compared with baseline, post-induction chemotherapy, and post-adjuvant chemotherapy (all P<0.001). In conclusion, elevated post-adjuvant chemotherapy SUA levels are associated with improved survival outcomes in patients with advanced-stage NPC. IMRT induces a transient decrease in SUA levels. These findings suggested that SUA levels may serve as a valuable prognostic biomarker for NPC.
扫码关注我们
求助内容:
应助结果提醒方式:
